Sarah Cannon Research Institute Announces Acquisition of Clinical Development Group

Expands clinical trial capabilities for innovative cancer research

NASHVILLE, Tenn.--()--Sarah Cannon Research Institute (SCRI) announced today the acquisition of Clinical Development Group (CDG), a strategic clinical trial consulting firm based in New Haven, CT. By joining SCRI, CDG provides expanded capabilities in global clinical and regulatory planning, trial project management, as well as access to therapeutic expertise, key opinion leadership and academic relationships.

“The addition of CDG is an important step for SCRI, as we continue to experience rapid growth in the management and oversight of clinical trials,” said SCRI CEO, Dee Anna Smith. “CDG’s strong passion and dedication to oncology research aligns with our values, and we are excited to add these talented members to our team.”

CDG President, Ann Cahill, has joined SCRI’s executive team in the role of Vice President, Program Development and will report to Chief Medical Officer, Howard A. Burris III, MD. Prior to founding CDG, Ann held several leadership positions in drug development with biopharmaceutical companies including Schering-Plough and Vion Pharmaceuticals.

“SCRI and CDG have a shared mission to advance therapies for patients through clinical oncology research,” said Cahill. “Together, we are integrating our unique capabilities to achieve such advancements and bring novel therapies to patients.”

In addition to Cahill, several other experienced members of CDG will join the SCRI Development Innovations business unit. While continuing to focus on existing projects, CDG’s team will add value and expertise to current and future SCRI projects. As a result of this acquisition, SCRI has opened an office in Cambridge, MA to better serve our pharmaceutical and biotechnology partners.

About Sarah Cannon Research Institute

Sarah Cannon Research Institute (SCRI) is a global strategic research organization focusing on advancing therapies for patients. It is one of the world’s leading clinical research programs, conducting community-based clinical trials in oncology and cardiology through affiliations with a network of more than 700 physicians in the United States and United Kingdom. Additionally, SCRI offers management, regulatory, and other research support services for drug development and industry sponsors and strategic investigator sites. For more information, please visit sarahcannonresearch.com.

Contacts

Sarah Cannon Research Institute
Gabrielle Hannafan, 615-524-4235
gabrielle.hannafan@scresearch.net

Release Summary

Sarah Cannon Research Institute (SCRI) announced today the acquisition of Clinical Development Group (CDG), a strategic clinical trial consulting firm based in New Haven, CT.

Sharing

Contacts

Sarah Cannon Research Institute
Gabrielle Hannafan, 615-524-4235
gabrielle.hannafan@scresearch.net